… like thrombocytosis, neutropenia, and neutropenia are infrequent. Here we report a rare case
of drug-induced thrombocytosis … This case emphasizes that any patient with thrombocytosis …

… Haematologic adverse events such as thrombocytosis, haemolysis, anaemia, and
neutropenia are rare. Our focus in this report is on ertapenem-induced thrombocytosis, which is …

… Data Synthesis: Drug-induced thrombocytosis, a form of reactive thrombocytosis cannot be
… of reactive thrombocytosis. In all, 43 case reports of drug-induced thrombocytosis from a wide …

… , direct cell toxicity, arteriolar thrombosis and metabolic alterations such as hypertriglyceridemia.
… The absence of thrombosis, and hypertriglyceridemia would rule out other possible …

… can be diagnosed on clinical evidence; however, the type of thrombocytosis and the cause
of secondary thrombocytosis are always difficult to determine. Patients with thrombocytosis …

… In this systematic review, we synthesize the existing literature on ertapenem-induced … imaging
within 1 year, anemia, and thrombocytopenia, but not older age and renal dysfunction [16]. …

… Symptoms of ertapenem-induced encephalopathy typically improve within two to 14 days …
evaluation strongly support our patient's diagnosis of ertapenem-induced encephalopathy. …

DISCUSSION To the best of our knowledge, there is no recommendation on how SGA
medications should be managed during HD in chronic kidney disease patients. Ziprasidone is a …

… Lee et al 10 conducted the largest retrospective study to date quantifying the incidence of
ertapenem-induced seizures in 1706 patients treated with ertapenem. The authors have …

… as cerebral gliosis, previous cerebrovascular thrombosis, and hemorrhage, compared with …
attempt to estimate the true risk of ertapenem-induced seizures in older patients. Nevertheless…